Why the first funding round matters more than it looks
The subject of this series is the financing path of academic start-ups: ventures founded by people with academic backgrounds or built around research-linked intellectual property. The immediate focus is the first funding round and the practical judgment it supports: a reader should be able to see why the first source of money can shape whether a research idea becomes a company, which next source of capital becomes reachable, and how later success should be measured. The important question is therefore not simply, “Did this venture get funded?” It is, “What did that first funding choice make possible, and what problem did it leave unsolved?”
The subject is a path, not a cheque
An academic start-up begins with an unusual combination of promise and uncertainty. Its founders may be close to a scientific discovery, a new method, or a technical capability that could become a product. But the route from discovery to a sellable product is rarely short. It may require experiments, prototypes, regulatory work, specialised equipment, customer education, and a team that can translate research into a commercial proposition. A private investor must finance that work before its outcome is easy to observe.
The term “academic start-up” also covers two related situations that should not be confused. In the OECD analysis, an academic start-up is primarily one with at least one founder holding a PhD or doctoral degree. An academic research-linked start-up is identified separately through patents that are jointly filed with a university, cite a university patent, or cite scientific literature. A company can have a doctoral founder without holding such a patent; another company can use university-derived intellectual property without having a PhD founder. The distinction matters because a founder’s networks and business experience are one financing signal, while a patent can make a technical asset more legible to investors. They may overlap, but they are not interchangeable.
The OECD study follows these ventures through a sequence of financing events. It uses information on 81,318 start-ups founded in OECD countries between 1990 and 2022, including 8,065 with an academic founder—about 9.9% of the sample. That scale changes the question. Instead of treating one celebrated spin-off as representative, the analysis asks whether academic entrepreneurship has a recurring financing pattern across countries, sectors, and time.
A financing path has several distinct states. First, an idea or research project must become a formal company. Then the company must obtain an initial source of money or support. Later, it may need a second round, growth capital, a strategic buyer, or access to public markets. These are not interchangeable definitions of success. A grant can be effective at getting a company into existence even if it does not prepare the company for private equity. Conversely, a venture can raise a large first round and still fail to build the product, relationships, or market evidence required for the next one.
The paradox: easier access, harder continuation
The broad OECD pattern is counterintuitive. After controlling for founding cohort, country, sector, patents, academic patents, team size, and whether a founder has an MBA, academic start-ups have a 5.2 percentage-point higher probability of receiving some funding than non-academic start-ups. Before those controls, the difference is 21.7 percentage points, which shows that observable characteristics—especially sector, intellectual property, and team composition—explain much of the raw gap.
Yet greater access does not translate into greater total funding. Among funded ventures with complete amount information, academic start-ups appear to raise about 55% more in the unadjusted comparison. Once the observed characteristics are included, that difference becomes small and statistically insignificant. First funding amounts are broadly similar after controls, while follow-on funding is significantly lower for academic start-ups. In other words, the financing problem is not well described as “academic founders cannot raise money.” It is closer to this: they can often find an early bridge, but may have more difficulty crossing to the capital needed for the next stage.
That pattern gives the first funding round a meaning beyond its face value. Money is also a signal, a relationship, a set of obligations, and an entry into a network. A grant may buy time to develop a prototype without giving up ownership. An accelerator may provide less cash but introduce the team to customers and investors. Equity may provide more capital and a partner with an incentive to help the company grow, while also creating dilution and pressure for a high-growth route. The first choice can therefore relieve one bottleneck while leaving the next one untouched—or make the next transition easier or harder.
The sequence is particularly important for academic start-ups because their strongest asset can also delay commercial proof. In the OECD data, academic founders are concentrated in health and biotechnology, energy, resources and sustainability, manufacturing, and information technology. These fields often involve substantial technical development and capital needs. Academic start-ups also produce more science-linked patents, while their founding teams are larger on average—2.8 founders compared with 1.7 for non-academic ventures—but less likely to include an MBA founder, 10% compared with 17%. These figures do not prove that a missing MBA causes a funding gap. They do show why technical competence and commercial competence should not be assumed to arrive in the same package.
The first round thus becomes a test of fit. Is the venture mainly short of time and prototype funding? Is it short of business planning, customer access, or investor relationships? Is the intellectual property sufficiently clear for an equity investor to price the opportunity? Or is the technology still too uncertain for private capital, making non-dilutive support the rational first bridge? The answer changes what a “successful” first round should accomplish.
Two kinds of evidence, one unresolved handoff
The two studies supporting this series answer different parts of the path. The OECD working paper maps financing relationships across a large, cross-country sample. Its adjusted results are informative about patterns—who receives which instrument, how quickly, and what tends to follow—but they are not randomized estimates that changing a founder’s academic status would change a funding outcome. Selection, missing networks, technology lead times, commercial strategy, and other unobserved factors may influence both the first instrument and later results.
The German study of the EXIST–Business Startup Grant addresses an earlier and narrower question: can targeted public support increase the probability that a pre-foundation academic project becomes a formally established company? It uses a regression-discontinuity design around the expert-score threshold for funding, comparing projects close to the boundary between funded and rejected applications. Across its model specifications, the estimated odds ratios for company formation range from 4.83 to 10.79, and the funded projects’ success probabilities are at least twice those of the comparison group. This is unusually strong evidence that the specific EGS intervention can change the formation outcome for projects near that selection threshold.
But company formation is not the same as long-term financing success. The EGS study measures whether a qualifying limited-liability company appears in the Commercial Register; it does not establish how quickly the company forms, whether it survives, how well it performs, or whether it later raises private capital. Its authors also note that the causal mechanism was not tested directly. The programme combines living support, project materials, coaching, university facilities, mentoring, and institutional anchoring. Those elements plausibly reduce financial risk and improve planning, product development, skills, and networks, but the study does not isolate the effect of each component.
This distinction prevents two opposite errors. The first is to dismiss grants because some grant-funded ventures later show weaker transitions to equity. A grant may have succeeded at the earlier task of keeping a high-risk project alive long enough to become a company. The second is to treat a strong company-formation result as proof that grants automatically produce growth capital. The OECD evidence points in the other direction: ventures that first receive grants are more likely to receive grants again and less likely to move to equity in the next funding event than ventures that first receive assistance. That is a financing-path association, not proof that grants cause private investment to disappear, but it is a warning that formation and continuation require different capabilities.
The central judgment of this series follows from that boundary. Academic start-ups should not be evaluated by asking which instrument is universally best. They should be evaluated by asking whether the first instrument matches the current bottleneck and whether it contains—or is paired with—a credible handoff to the next one. Early public funding may bridge the gap between research and company formation. Assistance, business education, industry networks, and investor access may determine whether the company can cross the next gap. Equity, debt, or public equity may matter later when the venture can show enough technical and commercial evidence to support larger commitments.
The first funding round is therefore a fork in a longer route. Its importance lies not only in the cash received, but in the sequence it starts: which risks are absorbed, which capabilities are built, which relationships are formed, and which future capital remains plausible. That is why the next question is not whether academic start-ups deserve support. It is what kind of bridge their particular combination of science, people, technology, and market uncertainty requires first.